<DOC>
	<DOCNO>NCT02847897</DOCNO>
	<brief_summary>The study intend assess safety efficacy CO2 AcuPulse laser treatment patient vaginal prolapse . Eligible subject receive 3 treatment session , 4 week apart 3 Follow Up visit , 1 , 3 , 6 month follow last treatment .</brief_summary>
	<brief_title>Evaluation Safety Efficacy Carbon Dioxide ( CO2 ) Acupulse Laser Treatment Vaginal Elasticity .</brief_title>
	<detailed_description>Following screen visit , eligible subject enrol study . Each subject receive 3 treatment 4 week apart 3 Follow Up visit , 1 , 3 , 6 month follow last treatment . Further demographic information patient history obtain subject ` electronical file .</detailed_description>
	<criteria>• Healthy postmenopausal woman define one following : A . ≥ 40 year old , last spontaneous menstrual bleeding occur least ≥ 12 month prior screen B . ≥ 45 year old , remember date last spontaneous menstrual bleeding provide lab result show folliclestimulating hormone ( FSH ) level &gt; 40 IU/L C. Underwent hysterectomy without oophorectomy provide lab result show serum FSH level &gt; 40IU/L D. Underwent bilateral oophorectomy least 12 week prior screen Presence one prolapse relate symptom ( e.g . dryness , itching , burning , dysuria dyspareunia ) At least 10 subject sample symptom urinary stress incontinence ( Stamey classification Grade =1 ) Negative urine analysis Normal Papanicolaou ( PAP ) test recent year Sexually active ( sex least month ) wish maintain active sexual life Able willing comply treatment/followup schedule requirement Vaginal Health Index Score ( VHIS ) &lt; 5 Active genital infection Subject present abnormal PAP result last three year follow finding accord Bethesda System ( 2001 ) classification : A. Atypical Squamous Cells Undetermined Significance ( ASCUS positive human papilloma virus ( HPV ) High Risk Positive B. Atypical Squamous Cellscannot exclude high grade squamous intraepithelial lesion C. Atypical Glandular Cells ( Endocervical , Endometrial otherwise specify ) D. Low Grade squamous intraepithelial lesion ( LSIL ) E. High Grade squamous intraepithelial lesion ( HSIL ) F. Carcinoma Systemic steroid use within last 3 month Systemic hormonal replacement therapy within last 3 month Local hormonal replacement therapy within last month Vaginal lubricant within 7 day prior enrollment Recurring urinary tract infection recur infection genital herpes candida ( &gt; 2 episode recent year ) Pelvic organ prolapse ( POP ) &gt; II accord pelvic organ prolapse quantification system Transvaginal mesh implant Serious systemic disease chronic condition could interfere study compliance Taken part clinical trial within 30 day prior screen . Any reason , opinion investigator , prevents subject participate study compromise subject safety</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>